InMed Pharmaceuticals (INM) Retained Earnings (2021 - 2025)
Historic Retained Earnings for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to -$119.0 million.
- InMed Pharmaceuticals' Retained Earnings fell 740.07% to -$119.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$119.0 million, marking a year-over-year decrease of 740.07%. This contributed to the annual value of -$117.2 million for FY2025, which is 748.3% down from last year.
- InMed Pharmaceuticals' Retained Earnings amounted to -$119.0 million in Q3 2025, which was down 740.07% from -$117.2 million recorded in Q2 2025.
- InMed Pharmaceuticals' 5-year Retained Earnings high stood at -$77.8 million for Q3 2021, and its period low was -$119.0 million during Q3 2025.
- For the 5-year period, InMed Pharmaceuticals' Retained Earnings averaged around -$102.3 million, with its median value being -$103.9 million (2023).
- In the last 5 years, InMed Pharmaceuticals' Retained Earnings tumbled by 2459.23% in 2022 and then crashed by 601.24% in 2024.
- InMed Pharmaceuticals' Retained Earnings (Quarter) stood at -$82.1 million in 2021, then dropped by 20.65% to -$99.1 million in 2022, then dropped by 6.41% to -$105.4 million in 2023, then fell by 7.51% to -$113.3 million in 2024, then decreased by 5.0% to -$119.0 million in 2025.
- Its Retained Earnings was -$119.0 million in Q3 2025, compared to -$117.2 million in Q2 2025 and -$115.4 million in Q1 2025.